[1] Hosokawa K,Yamazaki H,Mochizuki K,et al.Successful treatment of Trichosporon fungemia in a patient with refractory acute myeloid leukemia using voriconazole combined with liposomal amphotericin B[J].Transpl Infect Dis,2012,14(2):184-187.
[2] Ogawa T,Takezawa K,Tojima I,et al.Successful treatment of rhino-orbital mucormycosis by a new combination therapy with liposomal amphotericin B and micafungin[J].Auris Nasus Larynx,2012,39(2):224-228.
[3] Zhang J,Xi L,Lu C,et al.Successful treatment for chromoblastomycosis caused by Fonsecaea monophora:a report of three cases in Guangdong,China[J].Mycoses,2009,52(2):176-181.
[4] Bhat SV,Paterson DL,Rinaldi MG,et al.Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease:successful combination therapy with voriconazole and terbinafine[J].Scand J Infect Dis,2007,39(1):87-90.
[5] Berenbaum MC.A method for testing for synergy with any number of agents[J].J Infect Dis,1978,137(2):122-130.
[6] Li Y,Wan Z,Li R.In vitro activities of nine antifungal drugs and their combinations against Phialophora verrucosa[J].Antimicrob Agents Chemother,2014,58(9):5609-5612.
[7] Tamura T,Asahara M,Yamamoto M,et al.In vitro susceptibility of dermatomycoses agents to six antifungal drugs and evaluation by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dermatophytes[J].Microbiol Immunol,2014,58(1):1-8.
[8] Nguyen MH,Barchiesi F,McGough DA,et al.In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var.neoformans[J].Antimicrob Agents Chemother,1995,39(8):1691-1695.
[9] Clinical and Laboratory Standards Institute.Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi;Approved Standard,2nd ed.CLSI document M38-A2[S].Clinical and Laboratory Standards Institute,Wayne,PA,2008.
[10] Clinical and Laboratory Standards Institute.Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts;Approved Standard,3rd ed.CLSI document M27-A3[S].Clinical and Laboratory Standards Institute,Wayne,PA,2008.
[11] Leeming JP,Notman FH.Improved methods for isolation and enumeration of Malassezia furfur from human skin[J].J Clin Microbiol,1987,25(10):2017-2019.
[12] Miranda KC,de Araujo CR,Costa CR,et al.Antifungal activities of azole agents against the Malassezia species[J].Int J Antimicrob Agents,2007,29(3):281-284.
[13] Evans EG.Resistance of Candida species to antifungal agents used in the treatment of onychomycosis:a review of current problems[J].Br J Dermatol,1999,141(Suppl 56):33-35.
[14] Czaika V,Tietz HJ,Schmalreck A,et al.Antifungal susceptibility testing in chronically recurrent vaginal candidosis as basis for effective therapy[J].Mycoses,2000,43(Suppl 2):45-50.
[15] Gupta AK,Kohli Y.In vitro susceptibility testing of ciclopirox,terbinafine,ketoconazole and itraconazole against dermatophytes and nondermatophytes,and in vitro evaluation of combination antifungal activity[J].Br J Dermatol,2003,149(2):296-305.
[16] Cuenca-Estrella M.Combinations of antifungal agents in therapy——what value are they?[J].J Antimicrob Chemother,2004,54(5):854-869.
[17] Yu J,Li R,Zhang M,et al.In vitro interaction of terbinafine with itraconazole and amphotericin B against fungi causing chromoblastomycosis in China[J].Med Mycol,2008,46(7):745-747.
[18] Zhang X,Huang H,Feng P,et al.In vitro activity of itraconazole in combination with terbinafine against clinical strains of itraconazole-insensitive Sporothrix schenckii[J].Eur J Dermatol,2011,21(4):573-576.
[19] Scheid LA,Mario DA,Kubica TF,et al.In vitro activities of antifungal agents alone and in combination against fluconazole-susceptible and-resistant strains of Candida dubliniensis[J].Braz J Infect Dis,2012,16(1):78-81.
[20] Ahmed SA,Kloezen W,Fahal AH,et al.In vitro interaction of currently used azoles with terbinafine against Madurella mycetomatis[J].Antimicrob Agents Chemother,2015,59(2):1373-1374.
[21] Odds FC.Synergy,antagonism,and what the chequerboard puts between them[J].J Antimicrob Chemother,2003,52(1):1. |